OTCPK:PARN.F

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Parnell Pharmaceuticals Holdings Ltd, a veterinary pharmaceutical company, focuses on developing, manufacturing, and commercializing various animal health solutions. More Details


Snowflake Analysis

Weak fundamentals or lack of information.


Similar Companies

Share Price & News

How has Parnell Pharmaceuticals Holdings's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: PARN.F is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 80% a week.

Volatility Over Time: PARN.F's weekly volatility has decreased from 96% to 80% over the past year, but is still higher than 75% of US stocks.


Market Performance


7 Day Return

14.3%

PARN.F

2.9%

US Pharmaceuticals

1.5%

US Market


1 Year Return

195.7%

PARN.F

6.9%

US Pharmaceuticals

22.3%

US Market

Return vs Industry: PARN.F exceeded the US Pharmaceuticals industry which returned 6.2% over the past year.

Return vs Market: PARN.F exceeded the US Market which returned 22.1% over the past year.


Shareholder returns

PARN.FIndustryMarket
7 Day14.3%2.9%1.5%
30 Day325.0%3.6%8.8%
90 Day54.5%3.3%10.8%
1 Year195.7%195.7%9.7%6.9%25.1%22.3%
3 Year-26.1%-26.1%25.9%16.8%49.5%39.6%
5 Year-92.5%-92.5%39.3%23.9%105.8%83.3%

Long-Term Price Volatility Vs. Market

How volatile is Parnell Pharmaceuticals Holdings's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Parnell Pharmaceuticals Holdings undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Parnell Pharmaceuticals Holdings is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Parnell Pharmaceuticals Holdings has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of PARN.F's management and see if the CEO's compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don't know where to start, we recommend reading through Parnell Pharmaceuticals Holdings regulatory filings here.
  • Explore potentially undervalued companies in the Pharmaceuticals & Biotech industry.

Future Growth

How is Parnell Pharmaceuticals Holdings forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

20.7%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Parnell Pharmaceuticals Holdings has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Parnell Pharmaceuticals Holdings performed over the past 5 years?

81.2%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: PARN.F is currently unprofitable.

Growing Profit Margin: PARN.F is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if PARN.F's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare PARN.F's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PARN.F is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (16.8%).


Return on Equity

High ROE: PARN.F's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Next Steps

Financial Health

How is Parnell Pharmaceuticals Holdings's financial position?


Financial Position Analysis

Short Term Liabilities: PARN.F has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: PARN.F has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: PARN.F has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: PARN.F's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Insufficient data to determine if PARN.F has enough cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if PARN.F has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Parnell Pharmaceuticals Holdings's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate PARN.F's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PARN.F's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PARN.F's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PARN.F's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of PARN.F's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

10.8yrs

Average board tenure


CEO

Brad McCarthy (44 yo)

2.92yrs

Tenure

Mr. Brad R. McCarthy, CPA, has been the Chief Financial Officer of Parnell Pharmaceuticals Holdings Ltd. since February 2010 and serves as its Chief Executive Officer since January 9, 2018 and Chief Accoun...


Board Members

NamePositionTenureCompensationOwnership
Alan Bell
Executive Chairman14.92yrsno datano data
Brad McCarthy
CEO, CFO2.92yrsno datano data
Anthony Hartnell
Independent Director2.92yrsno datano data

10.8yrs

Average Tenure

64yo

Average Age

Experienced Board: PARN.F's board of directors are seasoned and experienced ( 10.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Parnell Pharmaceuticals Holdings Ltd's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Parnell Pharmaceuticals Holdings Ltd
  • Ticker: PARN.F
  • Exchange: OTCPK
  • Founded: 2009
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$6.128m
  • Shares outstanding: 18.02m
  • Website: https://www.parnell.com

Number of Employees


Location

  • Parnell Pharmaceuticals Holdings Ltd
  • Century Estate
  • Unit 4
  • Alexandria
  • New South Wales
  • 2015
  • Australia

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PARN.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDJun 2014

Biography

Parnell Pharmaceuticals Holdings Ltd, a veterinary pharmaceutical company, focuses on developing, manufacturing, and commercializing various animal health solutions. The company operates through four segme...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/12/04 23:28
End of Day Share Price2020/12/04 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.